Modeling of developmental toxicity studies often requires simple parametric analyses of the dose-response relationship between exposure and probability of a birth defect but poses challenges because ...

Toxicity is a primary cause of compound attrition at all stages of drug discovery and development. Approximately 70% of all toxicity-related attrition occurs preclinically, and most of these findings ...

Over the last decade, there has been a resurgence of interest in polymyxins owing to the rapid rise in multi-drug resistant Gram-negative bacteria against which polymyxins offer a last-resort ...

AMeD syndrome is a severe genetic condition found in children that present with accelerated aging, global developmental delay and bone marrow failure, among others, progressing to Myelodysplastic ...

In developmental toxicology, methods based on dose-response modeling and quantitative risk assessment are being actively pursued. Among live fetuses, the presence of malformations and reduction in ...

Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective This review highlights strategies to integrate ...

Combining the convenience and throughput of multiwell assays with the benefits of a fully functioning organism Standard toxicity experiments carried out in typical cell culture experiments lack the ...

Cancer-related financial toxicity occurs frequently and is a key driver of inequities in access to care and disparities in treatment outcomes. Current practices to screen for financial toxicity are ...